Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 9,100 shares, a decrease of 79.8% from the October 15th total of 45,100 shares. Based on an average daily trading volume, of 150,800 shares, the short-interest ratio is presently 0.1 days.

Astellas Pharma Price Performance

Shares of OTCMKTS:ALPMY opened at $10.74 on Thursday. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. Astellas Pharma has a fifty-two week low of $9.15 and a fifty-two week high of $13.14. The firm has a 50-day simple moving average of $11.78 and a 200 day simple moving average of $10.95. The company has a market cap of $19.44 billion, a PE ratio of 18.20 and a beta of 0.36.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. The business had revenue of $3.11 billion during the quarter. On average, sell-side analysts anticipate that Astellas Pharma will post 0.62 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.